Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenus Regulatory News (GNS)

Share Price Information for Genus (GNS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,710.00
Bid: 1,722.00
Ask: 1,728.00
Change: -60.00 (-3.39%)
Spread: 6.00 (0.348%)
Open: 1,784.00
High: 1,784.00
Low: 1,710.00
Prev. Close: 1,770.00
GNS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Interim Management Statement

1 May 2009 07:00

RNS Number : 5549R
Genus PLC
01 May 2009
 



For immediate release 1 May 2009

Genus plc

('Genus' or 'the Company')

Interim Management Statement

Genus, a leading global animal genetics company, today publishes its interim management statement for the four month period ended 30 April 2009.

Trading performance

Genus continued to trade in line with the Board's expectations.

Based on results for the three months to 31 March 2009, trading followed the trend seen at the half year. Profits were well ahead of the prior year, driven by US Dollar and Euro strength against Sterling. In constant currency profits were at similar levels to the prior year. 

In the current economic environment, market conditions for Genus' customers in the USA and Western Europe remained challenging but continued to be less so in Genus' other markets.

Overall Porcine performance continued to be robust. In Bovine, the US dairy sector slowed as milk prices continued to fall This has resulted in increased price competition and trading down by some of Genus' US customers. The impact on profitability has been mitigated by the US productivity improvement programme commenced in January 2009.

Financial Position

Cash flow for the Group in the period was positive despite the payment of the Company's annual dividend in January 2009 and continued planned investment in growthThe Group's net debt at the end of March was £102.7m (31 December 2008: £99.3m). This marginal increase was due to the impact of exchange rate movements on debt levels.

Outlook

Given the challenging global economic environment, Genus expects the markets for its customers to remain challenging in the short term, particularly in the USA. However, the impact on Genus' business is being limited by the Group's geographic and product diversity as well as the robustness of its business model. 

There has been considerable media coverage regarding the recent outbreak of influenza in Mexico and a number of other countries. Dubbed 'swine flu' it is a human strain of an H1N1 flu virus which has been found in humans and cannot be caught by consuming meat products. 

None of Genus' pure line breeding animals is infected with influenza. They are kept under strict bio-security regimes in nucleus farms in the USA and Canada

Speculation regarding the impact of the outbreak has resulted in a reduction in pig prices and precautionary import bans of swine and pork products by some countries. Genus' extensive spread of worldwide multiplication farms makes it better placed than its competitors to maintain supplies in countries where such bans are in place

As a result, whilst keeping the situation under close review, Genus currently expects there to be no material impact on its business from the influenza outbreak and the trading outlook for the financial year remains in line with the Board's expectations.

Genus will announce its preliminary results for the year ending 30 June 2009 on 10 September 2009.

For further information please contact:

Genus plc Tel: 01256 345970

Richard Wood, Chief Executive

John Worby, Finance Director

Buchanan Communications Tel: 0207 466 5000

Charles Ryland, Isabel Podda

About Genus

Genus creates advances to animal breeding through biotechnology and sells added value products for livestock farming and food producers. Its non-Genetically Modified Organism (GMO) technology is applicable across all livestock species but is only commercialised by Genus in the bovine and porcine farming sectors.

Genus' worldwide sales are made in seventy countries under the trademarks "ABS"

(dairy and beef cattle) and "PIC" (pigs) and comprise semen and breeding animals with superior genetics to those animals currently in production. Customers' animals produce offspring with greater production efficiency, milk and meat output and quality and use these to supply the global dairy and meat supply chain. 

The Group's competitive edge has been created from the ownership and control of proprietary lines of breeding animals, the biotechnology used to improve them and the Group's global production and distribution network.

Headquartered in BasingstokeEngland, Genus companies operate in 30 countries on six continents, with research laboratories located in MadisonUSA.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSSDMFASSUSESL
Date   Source Headline
23rd Nov 20227:00 amRNSAGM Trading Update
3rd Nov 20227:00 amRNSRuthin Site Visit
14th Oct 202211:39 amRNSTR-1: Notification of Major Holdings
14th Oct 20227:00 amRNSAnnual Report and Annual General Meeting
15th Sep 202210:55 amRNSNotification of Major Holdings
14th Sep 20224:41 pmRNSDirector/PDMR Shareholding
13th Sep 20226:08 pmRNSDirector/PDMR Shareholding
8th Sep 20221:57 pmRNSNotification of Major Holdings
8th Sep 20227:00 amRNSPreliminary Results
2nd Sep 20229:05 amRNSTotal Voting Rights
2nd Aug 20227:00 amRNSAppointment of Joint Corporate Broker
1st Aug 202210:10 amRNSBlock listing Interim Review
21st Jul 202210:21 amBUSForm 8.3 - Genus Plc - CORRECTION
21st Jul 202210:05 amRNSHolding(s) in Company
20th Jul 20223:03 pmRNSNotification of Major Holdings
19th Jul 202211:57 amBUSForm 8.3 - Genus Plc
5th Jul 20222:10 pmRNSNotification of Major Holdings
1st Jul 20229:35 amRNSTotal Voting Rights
24th Jun 20223:42 pmRNSNotification of Major Holdings
6th Jun 20229:11 amRNSNotification of Major Holdings
1st Jun 202212:45 pmRNSNotification of Major Holdings
30th May 202212:18 pmRNSNotification of Major Holdings
17th May 20229:26 amRNSNotification of Major Holdings
21st Apr 20227:00 amRNSNotification of Major Holdings
19th Apr 20221:50 pmRNSNotification of Major Holdings
31st Mar 20221:34 pmRNSDirector Declaration
28th Mar 20225:36 pmRNSNotification of Major Holdings
8th Mar 20223:47 pmRNSNotification of Major Holdings
8th Mar 20221:13 pmRNSNotification of Major Holdings
24th Feb 20227:00 amRNSCollaboration between PIC and Olymel LP in Canada
24th Feb 20227:00 amRNSInterim Results
1st Feb 20224:57 pmRNSBlock listing Interim Review
4th Jan 20229:47 amRNSTotal Voting Rights
26th Nov 202110:18 amRNSDisclosure of Rights Attached to Equity Shares
24th Nov 20215:51 pmRNSDirector/PDMR Shareholding
24th Nov 20212:47 pmRNSResult of AGM
24th Nov 20212:30 pmRNSDirector/PDMR Shareholding
24th Nov 20217:00 amRNSAGM Trading Update
10th Nov 20212:28 pmRNSNotification of Major Holdings
15th Oct 20217:00 amRNSAnnual Report and Annual General Meeting
13th Oct 20215:56 pmRNSDirector/PDMR Shareholding
1st Oct 20213:58 pmRNSTotal Voting Rights
30th Sep 20219:59 amRNSDirector Declaration
29th Sep 20212:59 pmRNSNotification of Major Holdings
15th Sep 20214:45 pmRNSDirector/PDMR Shareholding
14th Sep 20214:32 pmRNSDirector/PDMR Shareholding
9th Sep 20217:00 amRNSPreliminary Results
1st Sep 20212:05 pmRNSTotal Voting Rights
2nd Aug 20214:00 pmRNSBlock listing Interim Review
2nd Aug 202110:09 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.